Cargando…
Effect of obesity on vedolizumab response in inflammatory bowel disease
BACKGROUND: Vedolizumab is used in inflammatory bowel disease (IBD), administered as a non-weight-based fixed dose. A higher body mass index (BMI) is associated with lower serum vedolizumab levels, but it is unclear whether it is associated with an unfavorable response to vedolizumab. We examined th...
Autores principales: | Levine, Louis J., Gaidos, Jill K. J., Proctor, Deborah D., Viana, Artur V., Al-Bawardy, Badr |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hellenic Society of Gastroenterology
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9062841/ https://www.ncbi.nlm.nih.gov/pubmed/35599926 http://dx.doi.org/10.20524/aog.2022.0699 |
Ejemplares similares
-
Use of Standardized Inflammatory Bowel Disease Endoscopy Scores in Clinical Practice
por: Gaidos, Jill K J, et al.
Publicado: (2023) -
Impact of thiopurine dose in anti-tumor necrosis factor combination therapy on outcomes in inflammatory bowel disease
por: Nawaz, Ahmad, et al.
Publicado: (2023) -
Novel and Emerging Therapies for Inflammatory Bowel Disease
por: Al-Bawardy, Badr, et al.
Publicado: (2021) -
The Impact of Inflammatory Bowel Disease Clinic On-site Vaccination Services
por: Hussain, Nadeen, et al.
Publicado: (2021) -
Early Flexible Sigmoidoscopy Improves Clinical Outcomes in Acute Severe Ulcerative Colitis
por: Sharma, Shreyak, et al.
Publicado: (2023)